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OBJECTIVES: The New Zealand (NZ) government drug pur-
chasing agency PHARMAC assesses products being considered
for reimbursement using criteria which include clinical need,
cost-effectiveness and drug budget impact and availability. All
major new pharmaceutical investments are evaluated by
PHARMAC using cost-utility analysis. The objective of this
study was to conduct a cost-utility analysis to examine the cost-
effectiveness of risperidone long-acting injection in the treatment
of non-compliant schizophrenia patients from a NZ health care
system perspective, using methodology that would be acceptable
to PHARMAC. METHODS: A 1-year, decision tree, cost-utility
model was developed to compare risperidone long-acting injec-
tion with a mixed comparator (conventional depot antipsy-
chotics, oral risperidone and oral olanzapine) in patients with a
history of relapse due to medication non-compliance. The event
probabilities (medication adherence, relapse, movement disor-
ders [extrapyramidal symptoms] and survival) were obtained
from comprehensive literature reviews. Local costs were
obtained from the Pharmaceutical Schedule and the New
Zealand Health Information Service (NZHIS). Utilities were
modeled based on existing literature. Development of the model
also involved a consultative process with PHARMAC staff. The
analyses were performed versus the mixed comparator as well as
each individual treatment option. Uncertainty was explored
using sensitivity analyses. RESULTS: Risperidone long-acting
injection was dominant compared with the mixed comparator,
oral risperidone and oral olanzapine. Compared with conven-
tional depots alone, the Incremental Cost Utility Ratio (ICUR)
was NZ$47,711. CONCLUSIONS: Risperidone long-acting
injection was considered a cost-effective treatment option in
New Zealand using PHARMAC’s acceptability threshold for
ICUR of less than NZ$20,000. Although the treatment was 
considered to have acceptable cost-effectiveness, funding is 
contingent upon budget being available in an environment in
which pharmaceutical spending has been static over the last 10
years.
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OBJECTIVES: To determine the cost-effectiveness of escitalo-
pram compared with citalopram in the management of severe
depression (Montgomery-Åsberg Depression Rating Scale
[MADRS] total score greater or less than 30) in the UK.
METHODS: A decision analytic model with a 6-month time
horizon was adapted from Hemels et al. (2004). The model
incorporated treatment paths and direct resource use (psychiatric
hospitalisations, medications, GP and psychiatrist visits, treat-
ment discontinuation and attempted suicide) associated with the
treatment of severe depression and indirect costs due to work
absenteeism. Main outcomes were clinical success (remission
[MADRS £ 12] at 6 months) and cost (2003 GBP) of treatment.
The analysis was performed from both a societal and National
Health Service (NHS) perspectives. Clinical data were derived
from a meta-analysis of 8-week head-to-head randomised clini-
cal trials and extrapolated to 6 months. Costs were derived from
standard UK price lists and literature. Societal costs of lost pro-
ductivity were calculated using the Human Capital approach.
RESULTS: At 6 months after start of treatment, the overall clin-
ical success remission rate was higher for escitalopram (53.7%)
than for citalopram (48.7%). From the NHS perspective, the
total expected cost per successfully treated patient was £146
(18.5%) lower for escitalopram (£786) compared with citalo-
pram (£931). From the societal perspective, the total expected
cost per successfully treated severely depressed patient was £238
(18.6%) lower for escitalopram (£1283) than for citalopram
(£1521). Multivariate sensitivity analyses demonstrated that in
>99% of the cases, escitalopram was dominant for both per-
spectives at all ranges of probabilities tested. Sensitivity analyses
demonstrated that the model was robust and that, for the soci-
etal perspective, escitalopram remained the dominant strategy,
even if citalopram had an acquisition cost of £0. CONCLU-
SIONS: The results of this study suggest that escitalopram is a
cost-effective antidepressant compared with citalopram in the
management of severe depression in the UK.
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OBJECTIVES: Antidepressant therapy is highly effective in
patients with major depressive disorder (MDD). Evidence has
shown that most patients stay on pharmacotherapy for less than
6 months even though clinical guidelines recommend treatment
for longer periods of time. The objective of this study was to
assess the impact of premature discontinuation of antidepressant
therapy on costs and outcomes in MDD patients. METHODS:
We created a UK adaptation of a simulation model to compare
the costs and outcomes associated with patients who respond to
treatment with a selective serotonin reuptake inhibitor (SSRI)
and discontinue treatment prematurely to those who respond to
SSRI’s and complete the recommended course of treatment.
Patients are outpatients and are assumed to follow treatment as
recommended by the clinical guidelines except when early dis-
continuation occurs. The model considers medication, primary
care physician visit, specialist (i.e., psychiatrist, hospital days,
suicide, etc.), and adverse event costs. Treatment efﬁcacy was
taken from published meta-analyses, and early discontinuation
was estimated from the published literature. Resource use was
estimated from the clinical guidelines and published literature.
Unit costs were drawn from standard published sources and
inﬂated to 2003 UK pounds. RESULTS: Over the course of 5
years, we observe that continuation patients (i.e. patients who
complete a recommended course of treatment) have 743 fewer
symptom days, 9 fewer disability days, and lower costs by $287
than discontinuation patients (i.e. patients who discontinue
early) when having relapses/recurrences. In the index episode,
continuation patients incur more costs than discontinuation
patients due to increase usage of drugs and physician. However,
patients who discontinue incur more costs later due to higher
relapse/recurrence rates. CONCLUSIONS: By encouraging
patients to complete a full course of drug therapy, patients will
incur fewer costs and fewer symptom and disability days.
